Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol

Olga V. Savinova, Kristi Fillaus, William S. Harris, Gregory C. Shearer

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome. Methods: Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction. Results: ERN reduced plasma apoB (-11%, p<0.05). Combo increased LDL apoE/apoB ratio (64%, p<0.01) and LDL apoA1/apoB (91%, p<0.05). ERN increased the apoC3 glycosylation index only in HDL (37%, p<0.05), whereas P-OM3 and Combo increased the index in whole plasma (48% and 49%, respectively, p<0.05 for both) and in every lipoprotein class (VLDL: 26%, p<0.01 and 26%, p<0.05; LDL: 55%, p<0.01 and 61%, p<0.01; HDL: 43%, p<0.001 and 44%, p<0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value. Conclusions: ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.

Original languageEnglish (US)
Pages (from-to)520-525
Number of pages6
JournalAtherosclerosis
Volume240
Issue number2
DOIs
StatePublished - Jun 1 2015

Fingerprint

Apolipoproteins
Niacin
Omega-3 Fatty Acids
HDL Cholesterol
Apolipoproteins B
HDL Lipoproteins
Triglycerides
Apolipoproteins E
Glycosylation
Lipoproteins
Apolipoprotein A-II
VLDL Lipoproteins
Apolipoprotein A-I
Proxy
Prescriptions
Electrophoresis
oxidized low density lipoprotein
Protein Isoforms
Esters
Body Mass Index

All Science Journal Classification (ASJC) codes

  • Cardiology and Cardiovascular Medicine

Cite this

@article{d1bc2146257d4019bb64c3004b4f7e57,
title = "Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol",
abstract = "Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome. Methods: Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction. Results: ERN reduced plasma apoB (-11{\%}, p<0.05). Combo increased LDL apoE/apoB ratio (64{\%}, p<0.01) and LDL apoA1/apoB (91{\%}, p<0.05). ERN increased the apoC3 glycosylation index only in HDL (37{\%}, p<0.05), whereas P-OM3 and Combo increased the index in whole plasma (48{\%} and 49{\%}, respectively, p<0.05 for both) and in every lipoprotein class (VLDL: 26{\%}, p<0.01 and 26{\%}, p<0.05; LDL: 55{\%}, p<0.01 and 61{\%}, p<0.01; HDL: 43{\%}, p<0.001 and 44{\%}, p<0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value. Conclusions: ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.",
author = "Savinova, {Olga V.} and Kristi Fillaus and Harris, {William S.} and Shearer, {Gregory C.}",
year = "2015",
month = "6",
day = "1",
doi = "10.1016/j.atherosclerosis.2015.04.793",
language = "English (US)",
volume = "240",
pages = "520--525",
journal = "Atherosclerosis",
issn = "0021-9150",
publisher = "Elsevier Ireland Ltd",
number = "2",

}

Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol. / Savinova, Olga V.; Fillaus, Kristi; Harris, William S.; Shearer, Gregory C.

In: Atherosclerosis, Vol. 240, No. 2, 01.06.2015, p. 520-525.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effects of niacin and omega-3 fatty acids on the apolipoproteins in overweight patients with elevated triglycerides and reduced HDL cholesterol

AU - Savinova, Olga V.

AU - Fillaus, Kristi

AU - Harris, William S.

AU - Shearer, Gregory C.

PY - 2015/6/1

Y1 - 2015/6/1

N2 - Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome. Methods: Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction. Results: ERN reduced plasma apoB (-11%, p<0.05). Combo increased LDL apoE/apoB ratio (64%, p<0.01) and LDL apoA1/apoB (91%, p<0.05). ERN increased the apoC3 glycosylation index only in HDL (37%, p<0.05), whereas P-OM3 and Combo increased the index in whole plasma (48% and 49%, respectively, p<0.05 for both) and in every lipoprotein class (VLDL: 26%, p<0.01 and 26%, p<0.05; LDL: 55%, p<0.01 and 61%, p<0.01; HDL: 43%, p<0.001 and 44%, p<0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value. Conclusions: ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.

AB - Objective: Prescription omega-3 acid ethyl esters (P-OM3) and extended release niacin (ERN) both have beneficial effects on plasma lipids and lipoproteins. The purpose of this study was to describe the effects of mono- and combination (Combo) therapy of these agents in patients with the metabolic syndrome. Methods: Very low density (VLDL), intermediate/low density (IDL/LDL, hereafter LDL), and high density lipoproteins (HDL) were isolated from 56 overweight patients with elevated triglyceride/HDL-C ratios at baseline and after 16 weeks of treatment with placebo, ERN (2g/day), P-OM3 (4g/day), or Combo and then analyzed by quantitative electrophoresis for apolipoproteins (apo) A1, A2, B, C2, C3 and E. Total plasma concentrations and the ratios of each apo with apoB (in VLDL and LDL) and with apoA1 (in HDL) were calculated. An apoC3 glycosylation index (a ratio between di- and mono-sialylated isoforms) was also determined in plasma and in each lipoprotein fraction. Results: ERN reduced plasma apoB (-11%, p<0.05). Combo increased LDL apoE/apoB ratio (64%, p<0.01) and LDL apoA1/apoB (91%, p<0.05). ERN increased the apoC3 glycosylation index only in HDL (37%, p<0.05), whereas P-OM3 and Combo increased the index in whole plasma (48% and 49%, respectively, p<0.05 for both) and in every lipoprotein class (VLDL: 26%, p<0.01 and 26%, p<0.05; LDL: 55%, p<0.01 and 61%, p<0.01; HDL: 43%, p<0.001 and 44%, p<0.001, respectively). All findings were significant after adjustment for age, sex, body mass index (BMI), smoking, medications, and baseline apo value. Conclusions: ERN produced a beneficial reduction in plasma apoB. The enrichment of LDL with apoE and apoA1 was unique to the Combo group and might be beneficial owing to the atheroprotective properties of apoE and HDL2 (a likely source of apoA1 in LDL fraction). The effect of therapies on the apoC3 glycosylation index is a novel finding, the implications of which will require further study.

UR - http://www.scopus.com/inward/record.url?scp=84928523058&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84928523058&partnerID=8YFLogxK

U2 - 10.1016/j.atherosclerosis.2015.04.793

DO - 10.1016/j.atherosclerosis.2015.04.793

M3 - Article

C2 - 25932792

AN - SCOPUS:84928523058

VL - 240

SP - 520

EP - 525

JO - Atherosclerosis

JF - Atherosclerosis

SN - 0021-9150

IS - 2

ER -